Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain.

abstract：INTRODUCTION:Switching drugs from prescription to non-prescription status (Rx-to-OTC) presents a unique set of challenges and opportunities to policy-makers and the industry in terms of managing health outcomes, pharmaceutical spending, and steering of consumer choices of therapy. Decision-analytic models are used to a...

journal_title：Journal of medical economics

authors： Cohen J,Millier A,Karray S,Toumi M

更新日期：2013-01-01 00:00:00

abstract：:Aims: Cumulative exogenous factor VIII (FVIII) exposure is an important predictor of developing neutralizing antibodies (inhibitors) to FVIII in patients with persons with hemophilia A (PwHA). The aim of this study was to model the costs of emicizumab versus FVIII prophylaxis and total treatment costs for patients wit...

journal_title：Journal of medical economics

authors： Patel AM,Corman SL,Chaplin S,Raimundo K,Sidonio RF

更新日期：2019-12-01 00:00:00

abstract：AIMS:Tuberous sclerosis complex (TSC) is a multi-organ autosomal-dominant, genetic disorder with incomplete penetrance. The multiple manifestations of TSC and impacts to numerous organ systems represent significant disease, healthcare, and treatment burden. The economic and employment burden of the disease on individua...

journal_title：Journal of medical economics

authors： Skalicky AM,Rentz AM,Liu Z,Said Q,Nakagawa JA,Frost MD,Wheless JW,Dunn DW

更新日期：2018-10-01 00:00:00

abstract：OBJECTIVES:Two anti-cancer drugs are currently approved for the treatment of HER2-positive metastatic breast cancer (MBC): trastuzumab-based therapy (TBT) administered intravenously as first line therapy until disease progression and lapatinib, an oral self-administered dual therapy with capecitabine (L+C) as second in...

journal_title：Journal of medical economics

authors： Benjamin L,Buthion V,Iskedjian M,Farah B,Rioufol C,Vidal-Trécan G

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Neuroblastoma (NB) is notorious in childhood cancer because of its high incidence and poor prognosis. The Children's Oncology Group reported that the 3-year OS in the high-risk (HR) group is 50%, and the HR-NB with bone marrow metastasis in our center is 43.1%. Thousands of families in China suffer from the ...

journal_title：Journal of medical economics

authors： Jiang C,Cai S,Duan C,Xu N,Zhou Y,Peng X,Ma X

更新日期：2020-09-01 00:00:00

abstract：:Aims: To evaluate total costs and health consequences of a colorectal cancer (CRC) screening program with colonoscopy, fecal immunochemical tests (FIT), and expanded use of multitarget stool DNA (mt-sDNA) from the perspectives of Integrated Delivery Networks (IDNs) and payers in the United States.Materials and methods...

journal_title：Journal of medical economics

authors： Hathway JM,Miller-Wilson LA,Jensen IS,Ozbay B,Regan C,Jena AB,Weinstein MC,Parks PD

更新日期：2020-06-01 00:00:00

abstract：OBJECTIVE:To quantify the health economic impact of managing cow milk allergy (CMA) in South Africa, from the perspective of healthcare insurers in both the private and public sectors and parents/carers of CMA sufferers. METHODS:A decision model depicting the management of CMA in South Africa was constructed, using in...

journal_title：Journal of medical economics

authors： Sladkevicius E,Guest JF

更新日期：2010-01-01 00:00:00

abstract：:Aims: This study aimed to examine the long-term clinical and economic burden of adults with congenital heart disease (ACHD) in Hong Kong. Methods: It retrospectively analyzed 336 consecutive ACHD patients who attended the Adult Congenital Heart Clinic between January 1, 2009 and December 31, 2014. Direct medical costs...

journal_title：Journal of medical economics

authors： Lee VWY,Yan BP,Fong TMC,Fung AKP,Cheng FWT

更新日期：2019-08-01 00:00:00

abstract：OBJECTIVES:To compare demographic and comorbidity profiles and healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% (lidocaine patch) versus patients not treated with the lidocaine patch. Repeat comparison for the subset of patients treated in long-term care (LTC) sett...

journal_title：Journal of medical economics

authors： Kirson NY,Ivanova JI,Birnbaum HG,Wei R,Kantor E,Amy Puenpatom R,Ben-Joseph RH,Summers KH

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:EOX (epirubicin, oxaliplatin, Xeloda; capecitabine) and FOLFOX4 (5-fluorouracil (5-FU), leucovorin, oxaliplatin) are the common chemotherapy regimens used in the treatment of advanced gastric cancer (aGC) in Hong Kong. This study aimed to compare the costs of these therapies for aGC patients from both the he...

journal_title：Journal of medical economics

authors： Zhou KR,Cheng A,Ng WT,Kwok TY,Yip EY,Yao R,Leung PY,Lee VW

更新日期：2017-05-01 00:00:00

abstract：AIMS:Fast-acting insulin analogues (FAIAs) reduce hypoglycaemia and improve administration flexibility compared with short-acting human insulin (SHI). This analysis examines whether these benefits translate into cost offsets when comparing the total treatment costs for FAIA versus SHI used as basal-bolus therapy for tr...

journal_title：Journal of medical economics

authors： Christensen TE,Gundgaard J,Pilgaard T

更新日期：2011-01-01 00:00:00

abstract：OBJECTIVE:To assess the cost-effectiveness of insulin detemir compared with Neutral Protamine Hagedorn (NPH) insulin when initiating insulin treatment in people with type 2 diabetes mellitus (T2DM) in Denmark, Finland, Norway, and Sweden. METHODS:Efficacy and safety data were derived from a 20-week multi-centre random...

journal_title：Journal of medical economics

authors： Ridderstråle M,Jensen MM,Gjesing RP,Niskanen L

更新日期：2013-01-01 00:00:00

abstract：OBJECTIVE:To characterize patient and physician satisfaction with current standard-of-care botulinum toxin treatment regimens for symptom control in patients with post-stroke spasticity using structured interviews with patients and physicians. RESEARCH DESIGN AND METHODS:Two cross-sectional surveys were conducted in C...

journal_title：Journal of medical economics

authors： Bensmail D,Hanschmann A,Wissel J

更新日期：2014-09-01 00:00:00

abstract：OBJECTIVE:To compare outcomes between patients with type 2 diabetes mellitus (T2DM) using fixed-dose combination (FDC) and loose-dose combination (LDC) products. METHODS:This retrospective cohort study used MarketScan Commercial and Medicare Supplemental data from January 1, 2009-December 31, 2013. The identified popu...

journal_title：Journal of medical economics

authors： Lokhandwala T,Smith N,Sternhufvud C,Sörstadius E,Lee WC,Mukherjee J

更新日期：2016-01-01 00:00:00

abstract：OBJECTIVE:To estimate the economic implications of introducing dabigatran etexilate ('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial fibrillation based on results of the RE-LY trial. METHODS:The lifetime cost and outcomes of dabigatran and warfarin were estimated using a previous...

journal_title：Journal of medical economics

authors： Langkilde LK,Bergholdt Asmussen M,Overgaard M

更新日期：2012-01-01 00:00:00

abstract：OBJECTIVE:This study compared real-world treatment patterns and healthcare costs among biologic-naive psoriasis patients initiating apremilast or biologics. METHODS:A retrospective cohort study was conducted using the Optum Clinformatics™ claims database. Patients with psoriasis were selected if they had initiated apr...

journal_title：Journal of medical economics

authors： Wu JJ,Pelletier C,Ung B,Tian M

更新日期：2019-04-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:The cost effectiveness of pregabalin as an add-on to the standard treatment of Belgian patients with post-herpetic neuralgia (PHN) had been demonstrated in a previously published Markov model. The purpose of this study was to update that model with more recent cost data and clinical evidence, ...

journal_title：Journal of medical economics

authors： Chevalier P,Lamotte M,Van Campenhout H,Eyckerman R,Annemans L

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Alemtuzumab and natalizumab are approved as second-line therapies for relapsing-remitting multiple sclerosis (RRMS) patients in Iran who have shown an inadequate response to other disease-modifying therapy (DMT). In the absence of head-to-head trials, evaluations based on decision analytic modeling may be a ...

journal_title：Journal of medical economics

authors： Taheri S,Sahraian MA,Yousefi N

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Many countries have various requirements for local economic analyses to assess the value of a new health technology and/or to secure reimbursement. This study presents a case study of an economic model developed to assess the cost-effectiveness of posaconazole vs standard azole therapy (fluconazole/itraconaz...

journal_title：Journal of medical economics

authors： Papadopoulos G,Hunt S,Prasad M

更新日期：2013-01-01 00:00:00

abstract：:Background: Procedural efficiencies can contribute to cost reductions in transcatheter aortic valve replacement procedures (TAVR). The objective of this study is to determine operating room (OR) variable cost per minute in endovascular TAVR procedures, in a real-world hospital setting. Methods: Using Premier data from...

journal_title：Journal of medical economics

authors： Potter BJ,Ann Thompson C

更新日期：2019-10-01 00:00:00

abstract：OBJECTIVE:To estimate direct medical costs for patients with tuberous sclerosis complex (TSC) and surgical resection of subependymal giant-cell astrocytoma (SEGA). METHODS:This retrospective cohort study selected patients who had SEGA surgery and TSC claims between 2000-2011 from three large US nationwide claims datab...

journal_title：Journal of medical economics

authors： Sun P,Liu Z,Krueger D,Kohrman M

更新日期：2015-05-01 00:00:00

abstract：OBJECTIVE:To carry out a cost-utility analysis comparing initial treatment with solifenacin 5 mg/day vs oxybutynin immediate-release (IR) 15 mg/day for the treatment of patients with overactive bladder (OAB) from the perspective of the U.K. National Health Service (NHS). METHODS:A Markov model with six health states w...

journal_title：Journal of medical economics

authors： Hart WM,Abrams P,Munro V,Retsa P,Nazir J

更新日期：2013-10-01 00:00:00

abstract：OBJECTIVES:The purpose of this study is to report on long-term treatment patterns in a back pain population and to consider whether these may be considered as reflective of under-treatment of pain or poor pain control. METHODS:Data are from a commissioned recontact SELECT survey of persons who had previously reported ...

journal_title：Journal of medical economics

authors： Langley PC,Liedgens H

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Systemic Candida infections (SCI) occur predominantly in intensive care unit patients and are a common cause of morbidity and mortality. Recently, changes in Candida epidemiology with an increasing prevalence of SCI caused by Candida non-albicans species have been reported. Resistance to fluconazole and azol...

journal_title：Journal of medical economics

authors： Masterton RG,Casamayor M,Musingarimi P,van Engen A,Zinck R,Odufowora-Sita O,Odeyemi IA

更新日期：2013-11-01 00:00:00

abstract：INTRODUCTION:Lung cancer is a highly prevalent condition with non-small cell lung cancer (NSCLC), representing ∼ 80%. Given its high prevalence and poor survival rates, it is important to understand costs associated with NSCLC treatment. OBJECTIVES:To carry out an incidence-based study in three European countries: Fra...

journal_title：Journal of medical economics

authors： McGuire A,Martin M,Lenz C,Sollano JA

更新日期：2015-01-01 00:00:00

abstract：OBJECTIVE:The spectrum of diseases caused by Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) represents a large burden on healthcare systems around the world. Meningitis, bacteraemia, community-acquired pneumonia (CAP), and acute otitis media (AOM) are vaccine-preventable infectious diseases tha...

journal_title：Journal of medical economics

authors： Knerer G,Ismaila A,Pearce D

更新日期：2012-01-01 00:00:00

abstract：:Aims: This article aimed to examine the cost-effectiveness of rivaroxaban in comparison to warfarin for stroke prevention in Japanese patients with non-valvular atrial fibrillation (NVAF), from a public healthcare payer's perspective.Materials and methods: Baseline event risks were obtained from the J-ROCKET AF trial ...

journal_title：Journal of medical economics

authors： Hori M,Tanahashi N,Akiyama S,Kiyabu G,Dorey J,Goto R

更新日期：2020-03-01 00:00:00

abstract：OBJECTIVE:To investigate adherence to dornase alfa therapy among commercially-insured patients with cystic fibrosis (CF) and to examine the impact of adherence on health and economic outcomes. METHODS:This retrospective cohort analysis included CF patients with ≥1 dornase alfa (Pulmozyme) pharmacy claim between 1 Octo...

journal_title：Journal of medical economics

authors： Nasr SZ,Chou W,Villa KF,Chang E,Broder MS

更新日期：2013-01-01 00:00:00

abstract：OBJECTIVES:To perform a cost-utility analysis of a new formulation of mesalazine (Mezavant XL, MMX mesalazine) versus an existing oral mesalazine (Asacol; mesalazine) from the UK National Health Service perspective. METHODS:A 5-year Markov cohort model was developed. Costs were obtained from the literature and utiliti...

journal_title：Journal of medical economics

authors： Brereton N,Bodger K,Kamm MA,Hodgkins P,Yan S,Akehurst R

更新日期：2010-03-01 00:00:00

abstract：OBJECTIVES:Non-severe nocturnal hypoglycemic events (NSNHEs) may have a major impact on patients. The objective was to determine how NSNHEs affect diabetes management, sleep quality, functioning, and to assess if these impacts differ by diabetes type or country. METHODS:An internet survey to adults with diabetes in th...

journal_title：Journal of medical economics

authors： Brod M,Christensen T,Bushnell DM

更新日期：2012-01-01 00:00:00